Ligand Set For Partnership Opportunities After Completing On Pfenex

Sets Out Strategy And Revenue Drivers After Finalizing $500m Deal

Fresh from completing its acquisition of Pfenex, Ligand Pharmaceuticals has laid out the benefits that it expects to gain from the deal.    

Open door
THE PFENEX DEAL OPENS THE DOOR TO AT LEAST THREE NEW PARTNERSHIPS IN THE NEXT 12 MONTHS • Source: Shutterstock

Ligand Pharmaceuticals, Inc. expects to strike at least three new partnership deals over the coming year thanks to its acquisition of Pfenex Inc., which the biopharma company has just completed.

Specializing in “developing or acquiring technologies that help pharmaceutical companies discover and develop medicines,” Ligand earlier this year struck a...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.